141 related articles for article (PubMed ID: 30227362)
1. Antirheumatic Medicine Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector.
Olivier N; Lubbe M; Joubert R; Naudé A; Burger J
Value Health Reg Issues; 2018 Sep; 16():99-105. PubMed ID: 30227362
[TBL] [Abstract][Full Text] [Related]
2. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
3. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
4. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
Popp RA; Rascati K; Davis M; Patel U
Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
[TBL] [Abstract][Full Text] [Related]
5. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
6. The outpatient utilization of non-steroidal anti-inflammatory drugs in South Bačka District, Serbia.
Calasan J; Mijatović V; Horvat O; Varga J; Sabo A; Stilinović N
Int J Clin Pharm; 2011 Apr; 33(2):246-51. PubMed ID: 21744192
[TBL] [Abstract][Full Text] [Related]
7. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
Kamata Y; Minota S
Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
[TBL] [Abstract][Full Text] [Related]
8. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
9. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study.
Lang HC; Lee HC; Lee SS; Lin HY; Chiu YM
Int J Rheum Dis; 2016 Nov; 19(11):1112-1118. PubMed ID: 26890537
[TBL] [Abstract][Full Text] [Related]
10. Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector.
Meuwesen WP; du Plessis JM; Burger JR; Lubbe MS; Cockeran M
Int J Clin Pharm; 2016 Aug; 38(4):863-9. PubMed ID: 27091130
[TBL] [Abstract][Full Text] [Related]
11. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
[TBL] [Abstract][Full Text] [Related]
12. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
13. Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
Donges E; Staatz CE; Benham H; Kubler P; Hollingworth SA
Clin Exp Rheumatol; 2017; 35(6):907-912. PubMed ID: 28421991
[TBL] [Abstract][Full Text] [Related]
14. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
15. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
16. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
17. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
[TBL] [Abstract][Full Text] [Related]
19. Claims for disease-modifying therapy by Alberta non-insured health benefits clients.
Barnabe C; Healy B; Portolesi A; Kaplan GG; Hemmelgarn B; Weaselhead C
BMC Health Serv Res; 2016 Aug; 16(1):430. PubMed ID: 27557840
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
